Omeros Corp represents values of innovation, integrity, and commitment to improving global health. With a strong corporate philosophy, Omeros Corp aims to develop novel solutions for unmet medical needs and enhance patient outcomes. The company is dedicated to pioneering research and development, leveraging its expertise in pharmacology to address issues in fields like ophthalmology and pain management. Omeros Corp remains focused on driving scientific advancements, collaborating with healthcare professionals, and creating value for its patients, shareholders, and stakeholders alike. Through these principles, Omeros Corp strives to make a positive impact on the healthcare industry and the lives of individuals worldwide.

Omeros Corp is primarily present in the United States.

Omeros Corp, a leading biopharmaceutical company, has achieved numerous significant milestones. Since its inception, the company has made remarkable progress in the development and commercialization of innovative therapeutics. Notably, Omeros Corp has successfully launched and received approval for multiple products, such as Omidria, a widely used ophthalmic surgical drug. Furthermore, the company has also made notable advancements in its research pipeline, with promising drug candidates targeting various therapeutic areas. Omeros Corp's dedication to scientific excellence and patient care has garnered recognition and accolades within the industry. With a strong track record of achievements, Omeros Corp continues to drive innovation and improve healthcare outcomes.

Omeros Corp is a pharmaceutical company founded in 1994 and headquartered in Seattle, Washington. The company focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical indications. Omeros Corp is committed to addressing unmet medical needs and improving patients' lives. Over the years, the company has made significant advancements in the fields of ophthalmology, inflammation, and central nervous system disorders. With a strong research and development pipeline, Omeros Corp continues to strive for cutting-edge innovation and breakthrough treatments. This commitment has positioned the company as a leader in the biopharmaceutical industry, with a dedication to improving global health outcomes.

The main competitors of Omeros Corp in the market include companies such as Johnson & Johnson's Janssen Pharmaceuticals, Novartis AG, and Valeant Pharmaceuticals International Inc.

Omeros Corp is primarily active in the biopharmaceutical industry.

The business model of Omeros Corp is centered around developing and commercializing innovative pharmaceutical products. Omeros Corp focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, disorders of the central nervous system, and immune-related diseases. Their extensive research and development efforts aim to deliver novel treatment options to improve patient outcomes and quality of life. Omeros Corp strives to leverage their expertise in pharmacology and biology to develop transformative therapies and contribute to advancements in the healthcare industry.

Omeros KGV ir -1,33.

Omeros KUV ir 0.

AlleAktien kvalitātes vērtējums Omeros ir 5/10.

Pašreiz nevar aprēķināt apgrozījumu Omeros.

gaidāmā Omeros peļņa ir -178,33 milj. USD.

Omeros Corp is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic products. The company is headquartered in Seattle, Washington, with offices in Europe and Asia. Omeros Corp's business operations are determined by its three business segments: research and development, production, and marketing. Research and Development Omeros Corp's research and development segment aims to discover and develop innovative and effective therapeutics for the treatment of central nervous system, ophthalmology, and immunology diseases. The company has an extensive portfolio of products in its development pipeline, including ARTEMIS, MASP-2 inhibitors, and OMS721. ARTEMIS is an investigative product designed to enhance the efficacy of the analgesic drug Ibuprofen. The product is currently in the clinical trial phase. OMS721 is a preparation for the treatment of rare chronic kidney inflammation (IgA nephropathy) that is in the approval phase. The medication is also in Phase 3 studies for the treatment of thrombotic thrombocytopenic purpura (TTP), a disease characterized by the formation of blood clots in small blood vessels in the body. Production Omeros Corp operates a production facility in Dayton, New Jersey, specializing in the manufacture of antibiotics and generic drugs. The company also holds exclusive distribution rights for Omidria, a preparation for the prevention of pain during and after eye surgery. Omidria has been approved by the U.S. Food and Drug Administration (FDA) and is available worldwide. The medication generated revenues of $100.6 million in 2019. Marketing Omeros Corp's marketing segment is responsible for advertising, marketing, and promoting the company's products. Through a combination of traditional and digital marketing strategies, Omeros aims to bring its products to the medical community and successfully market them. The company has a dedicated team of sales representatives to ensure a strong presence in the market. Conclusion Overall, Omeros Corp has a broad portfolio of innovative medications that allows the company to potentially generate billions in revenue. The focus on researching and developing new drugs, producing existing products, and marketing Omidria has already driven growth for the company and could mean even more growth potential in the near future.

Omeros izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Omeros vai uzņēmums nedod dividendes.

Omeros ISIN ir US6821431029.

Omeros WKN ir A0NBFF.

Omeros simbols ir OMER.

Pēdējo 12 mēnešu laikā Omeros maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Omeros plāno maksāt dividendes 0 USD apmērā.

Omeros pašreizējā dividendu rentabilitāte ir .

Omeros maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Omeros pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Omeros tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Omeros apmērā 0 USD, kas tika izmaksāta 6.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 6.10.2024..

Pēdējās dividendes izmaksa notika 6.10.2024..

Gadā 2023, Omeros izmaksāja 0 USD dividendes.

Omeros dividendes tiek izmaksātas USD.